These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 10603734)

  • 41. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
    Soriano V; Maida I; Núñez M; García-Samaniego J; Barreiro P; Martín-Carbonero L; González-Lahoz J
    Antivir Ther; 2004 Dec; 9(6):987-92. PubMed ID: 15651757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.
    Martinot M; Marcellin P; Boyer N; Detmer J; Pouteau M; Castelnau C; Degott C; Aupérin A; Collins M; Kolberg J; Wilber J; Benhamou JP; Erlinger S
    Ann Intern Med; 1997 Jun; 126(11):874-81. PubMed ID: 9163288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
    Zhu Y; Chen S
    World J Gastroenterol; 2013 Dec; 19(47):8963-73. PubMed ID: 24379621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antiviral treatment of hepatitis C virus infection].
    Silvain C
    Rev Med Interne; 1999 Aug; 20 Suppl 3():331s-340s. PubMed ID: 10480183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
    Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
    Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
    J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan.
    Zafar A; Imran M; Zahoor S; Shah ZH; Ali M; Afzal MS
    Viral Immunol; 2018; 31(6):426-432. PubMed ID: 29920175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.
    Hügle T; Cerny A
    Rev Med Virol; 2003; 13(6):361-71. PubMed ID: 14625884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
    Pivert A; Payan C; Lunel F;
    Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.